Hafeez Shaista, McDonald Fiona, Lalondrelle Susan, McNair Helen, Warren-Oseni Karole, Jones Kelly, Harris Victoria, Taylor Helen, Khoo Vincent, Thomas Karen, Hansen Vibeke, Dearnaley David, Horwich Alan, Huddart Robert
The Institute of Cancer Research, London; The Royal Marsden NHS Foundation Trust, Sutton, Surrey.
The Royal Marsden NHS Foundation Trust, Sutton, Surrey.
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):115-122. doi: 10.1016/j.ijrobp.2017.01.239. Epub 2017 Feb 9.
We report on the clinical outcomes of a phase 2 study assessing image guided hypofractionated weekly radiation therapy in bladder cancer patients unsuitable for radical treatment.
Fifty-five patients with T2-T4aNx-2M0-1 bladder cancer not suitable for cystectomy or daily radiation therapy treatment were recruited. A "plan of the day" radiation therapy approach was used, treating the whole (empty) bladder to 36 Gy in 6 weekly fractions. Acute toxicity was assessed weekly during radiation therapy, at 6 and 12 weeks using the Common Terminology Criteria for Adverse Events version 3.0. Late toxicity was assessed at 6 months and 12 months using Radiation Therapy Oncology Group grading. Cystoscopy was used to assess local control at 3 months. Cumulative incidence function was used to determine local progression at 1 at 2 years. Death without local progression was treated as a competing risk. Overall survival was estimated using the Kaplan-Meier method.
Median age was 86 years (range, 68-97 years). Eighty-seven percent of patients completed their prescribed course of radiation therapy. Genitourinary and gastrointestinal grade 3 acute toxicity was seen in 18% (10/55) and 4% (2/55) of patients, respectively. No grade 4 genitourinary or gastrointestinal toxicity was seen. Grade ≥3 late toxicity (any) at 6 and 12 months was seen in 6.5% (2/31) and 4.3% (1/23) of patients, respectively. Local control after radiation therapy was 92% of assessed patients (60% total population). Cumulative incidence of local progression at 1 year and 2 years for all patients was 7% (95% confidence interval [CI] 2%-17%) and 17% (95% CI 8%-29%), respectively. Overall survival at 1 year was 63% (95% CI 48%-74%).
Hypofractionated radiation therapy delivered weekly with a plan of the day approach offers good local control with acceptable toxicity in a patient population not suitable for radical bladder treatment.
我们报告了一项2期研究的临床结果,该研究评估了影像引导下每周一次的大分割放疗在不适合根治性治疗的膀胱癌患者中的应用。
招募了55例T2 - T4aNx - 2M0 - 1期不适合膀胱切除术或每日放疗的膀胱癌患者。采用“当日计划”放疗方法,将整个(排空的)膀胱每周分6次照射至36 Gy。放疗期间每周评估急性毒性,在放疗后6周和12周使用3.0版不良事件通用术语标准进行评估。在6个月和12个月时使用放射肿瘤学组分级评估晚期毒性。在3个月时使用膀胱镜检查评估局部控制情况。使用累积发病率函数确定1年和2年时的局部进展情况。将无局部进展的死亡视为竞争风险。使用Kaplan - Meier方法估计总生存期。
中位年龄为86岁(范围68 - 97岁)。87%的患者完成了规定的放疗疗程。分别有18%(10/55)和4%(2/55)的患者出现泌尿生殖系统和胃肠道3级急性毒性。未观察到4级泌尿生殖系统或胃肠道毒性。在6个月和12个月时,分别有6.5%(2/31)和4.3%(1/23)的患者出现≥3级晚期毒性(任何类型)。放疗后局部控制率在评估患者中为92%(占总人群的60%)。所有患者1年和2年时局部进展的累积发病率分别为7%(95%置信区间[CI] 2% - 17%)和17%(CI 8% - 29%)。1年时总生存率为63%(95% CI 48% - 74%)。
对于不适合根治性膀胱治疗的患者群体,采用“当日计划”方法每周进行大分割放疗可实现良好的局部控制且毒性可接受。